Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype

J Neuropathol Exp Neurol. 2023 Nov 20;82(12):1037-1039. doi: 10.1093/jnen/nlad082.

Authors

Allison Shelbourn¹, Nicholas Nuechterlein¹, Carolina Angelica Parada², Jessica Eaton², Mallory Tucker², Manuel Ferreira², Patrick J Cimino¹

Affiliations

¹ Neuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
² Department of Neurological Surgery, University of Washington, Seattle, Washington, USA.

No abstract available

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Humans
Meningeal Neoplasms*
Meningioma*
Minichromosome Maintenance Complex Component 2

Substances

MCM2 protein, human
Minichromosome Maintenance Complex Component 2

Grants and funding